Retaspimycin瑞他霉素,857402-23-4

价格询价

品牌MedChemExpress(MCE)
产地美国
货号HY-15263
更新日期2025年12月05日

MedChemExpress LLC

品牌商

13 年钻石会员

Retaspimycin

CAS No. : 857402-23-4

MCE 国际站：Retaspimycin

产品活性：Retaspimycin 是一种有效的 Hsp90 抑制剂，对 Hsp90 和 Grp9 的 EC₅₀ 值均为 119 nM。

研究领域：Cell Cycle/DNA Damage | Metabolic Enzyme/Protease

作用靶点：HSP

In Vitro: Retaspimycin is a potent inhibitor of Hsp90, with EC₅₀s of 119 nM for both Hsp90 and Grp9. Retaspimycin (IPI-504) is cytocoxic to human multiple myeloma (MM) cell lines, with EC₅₀s of 307 ± 51 nM and 306 ± 38 nM, respectively, for MM1.s and RPMI-8226 cells. Retaspimycin (IPI-504, 10-100 nM) suppresses the growth of both trastuzumab-sensitive and -resistant cells in a dose-dependent manner. Retaspimycin (0-500 nM) decreases HER2 protein expression and suppresses both Akt and MAPKs pathways in both sensitive and trastuzumab-resistant cells.

In Vivo: Retaspimycin (IPI-504, 50 mg/kg, i.v.) causes selective tumor retention in RPMI-8226 tumor-bearing mice. Retaspimycin (IPI-504, 100 mg/kg, p.o., 3 times per week) reduces the tumor volume by 69% and and 84% of baseline values in GIST-882 and GIST-PSW xenografts, respectively. Furthermore, Retaspimycin in combination with imatinib inhibits tumor growth more significantly than Retaspimycin alone in GIST-PSW model, but no obvious difference is ovsrebed in the GIST-882 model. Retaspimycin also downregulates KIT in gastrointestinal stromal tumor (GIST). Retaspimycin (IPI-504, 50 mg/kg) shows antitumor activity in HCC1569 xenografts. IPI-504 (100 mg/kg, i.p.) effectively decreases the levels of HER2, p-Akt, and p-MAPKs in BT474R and BT474H1047R tumors.